Lilly Zyprexa Marketing Going “Back to Basics” With Focus On Efficacy
Executive Summary
Lilly is taking a "back to basics" approach on marketing for its atypical antipsychotic Zyprexa to grow U.S. market share
You may also be interested in...
Invega Approval Gives J&J A Year To Move Risperdal Patients To Paliperidone
J&J has slightly over one year to switch patients to Invega before its blockbuster atypical antipsychotic Risperdal loses patent protection
Invega Approval Gives J&J A Year To Move Risperdal Patients To Paliperidone
J&J has slightly over one year to switch patients to Invega before its blockbuster atypical antipsychotic Risperdal loses patent protection
Zyprexa Sales Will Decline In Second Half; Symbyax Starts Slow
Lilly is focusing on increasing the trial rate for Symbyax among primary care physicians and psychiatrists to help build sales of the bipolar depression combination product